American Academy of Pediatrics (2003). Red Book 2003 Report of the Committee on Infectious Diseases, 26th Edition, pp 523-528.
Canadian Communicable Disease Report, Statement of the recommended use of monoclonal anti-RSV antibody, 15 September 2003, Volume 29, ACS-7,8.
Position statement: Preventing hospitalizations for respiratory syncytial virus infection. Robinson Joan L, Le Saux Nicole; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Paediatr Child Health 2015; 20(6):321-26
Canadian Pediatric Society Position Statement. Use of palivizumab in children with congenital heart disease. Paediatrics & Child Health 2009; Vol 14 No 8.
Feltes TF, Cabalka AK, Meissner HC et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532-40.
Ryan VR, Langley JM, Dodds L, Andreou P. Estimating Respiratory Syncytial Virus –associated hospitalization in the first year of life among infants born at 32 – 35 weeks gestation. Pediatr Infect Dis J 2016;35:851-855 doi: 10.1097/INF.0000000000001186
Standard Operating Procedure. AbbVie Corporation. September 7, 2016.